Biometric Underwriting Data: Protective Value Explained

Every underwriting data source eventually faces the same accounting question: does it pay for itself in avoided mortality? For decades that question had a settled answer when it came to fluids and paramedical exams, and a far murkier one for everything else. Now that accelerated and instant-issue programs strip blood and urine out of the file, the burden of proof has shifted to alternative inputs, and biometric underwriting data sits squarely in the spotlight. The protective value debate is no longer about whether physiological signals are interesting. It is about whether captured vitals, behavioral biometrics, and derived risk markers can replace some of the protective value that paramed evidence used to deliver, and at what residual cost.

"An additional $2.6 billion of protective value can only be identified through paramed and laboratory underwriting evidence," reported Clinical Reference Laboratory in its protective value analysis, framing the exact gap that biometric signals are now being asked to close in fluidless programs.

That number is the benchmark the industry keeps circling back to. It quantifies the excess mortality hiding inside undiagnosed hypertension, diabetes, and renal impairment that self-reported applications miss. When a carrier removes the blood draw, it does not remove that excess mortality from the book. It simply removes the tool that used to find it. The strategic question for chief underwriting officers and reinsurers is which combination of biometric inputs recovers the largest share of that protective value without reintroducing the friction that killed placement rates in the first place.

What protective value means for biometric underwriting data

Protective value is the mortality savings a data source produces net of its cost. A protective value study measures it by re-underwriting a population with and without a given input, then comparing the predicted mortality of cases the input would have reclassified, declined, or rated. The classic study design comes from MIB's checking service work published through the Society of Actuaries, which established the template: identify the cases a source uniquely catches, attach a mortality multiple to them, and weigh that against the all-in cost of running the source on every applicant.

Biometric underwriting data changes the inputs to that equation in three ways. First, the marginal cost per applicant is low because a smartphone-based capture has no phlebotomist, no kit, and no lab turnaround. Second, the signal is collected at the moment of application rather than days later, which compresses the cycle and reduces not-taken rates. Third, the signal is continuous and physiological rather than categorical and self-reported, which means it can surface risk that an applicant either does not know about or chooses not to disclose.

The catch is that biometric risk signals do not measure the same things a blood panel measures. A contactless scan does not return an A1C or a cotinine level. It returns vitals and derived patterns such as resting heart rate, heart rate variability, estimated blood pressure ranges, and respiratory rate. The protective value case rests on how well those physiological markers correlate with the mortality drivers that fluids used to catch directly.

Data source	What it captures	Marginal cost per applicant	Disclosure dependence	Protective value profile
Self-reported questionnaire	Stated history and behavior	Near zero	Total	Low; anti-selection erodes signal
Paramed plus fluids	Direct lab biomarkers	High; kit, phlebotomy, lab	Low	High; the established benchmark
Biometric vitals capture	Live physiological signals	Low; software only	Low to moderate	Moderate and rising; complements other data
Behavioral and wearable data	Activity, sleep, trend patterns	Low to moderate	Moderate	Emerging; strong for segmentation
MIB and Rx history	Prior application and pharmacy records	Low	Low	Established for verification and catch

The table makes the strategic position of biometric underwriting data clear. It is the only column besides fluids that combines low disclosure dependence with a meaningful physiological signal, and it does so at software-level cost. That combination is why reinsurers are paying attention even where validation is still maturing.

Why self-reported answers underperform

Self-reported answers fail in a predictable direction. Applicants under-report weight, smoking, and family history, and they cannot report conditions they have never been diagnosed with. The result is a signal that degrades exactly where it matters most, in the impaired and borderline cases that drive excess claims. Biometric capture sidesteps the disclosure problem because the applicant cannot negotiate with their own resting heart rate.

Where lab markers still lead

Lab markers retain an advantage for specific, well-defined impairments. A1C for diabetes, NT-proBNP for cardiac risk, and cotinine for nicotine use are direct measurements with decades of mortality experience behind them. Biometric vitals approach these conditions indirectly, through the cardiovascular and metabolic patterns they produce. For now, the honest framing is complementary rather than substitutive: biometric underwriting data recovers a portion of protective value cheaply and catches different cases, while fluids remain the gold standard for the specific markers they measure.

Industry applications of biometric risk signals

Triage and waterfall placement

The most common application places biometric capture early in a digital health waterfall. A clean physiological profile routes an applicant straight to an instant decision, while abnormal vitals trigger a reflexive request for fluids or an APS. Used this way, biometric underwriting data does not have to match fluids on its own. It only has to identify which applicants safely skip them, which is a lower and more defensible bar.

Mortality protective value recovery in fluidless programs

For fully fluidless products, biometric signals carry more weight because there is no reflexive lab behind them. Here the protective value case depends on combining vitals with MIB, prescription history, and electronic health records so that no single source bears the full mortality burden. Munich Re's research on next-generation data sources notes that wearable physical activity data alone can segment mortality risk across demographics, sometimes more predictively than traditional measures, which supports a layered design.

Reinsurer audit and treaty negotiation

Reinsurers increasingly want to see the protective value math before they extend automatic capacity to a biometric-driven program. That means documented capture quality, signal stability, and a clear account of which cases the biometric layer catches that the application misses. Carriers that can produce a protective value study tend to negotiate better treaty terms than those relying on vendor claims.

Current research and evidence

The evidence base for contactless vitals accuracy is uneven and worth reading honestly. Remote photoplethysmography, the camera-based technique behind most smartphone vitals, shows strong agreement with ECG for pulse rate and heart rate variability. Clinical validation work published in PMC on rPPG pulse rate monitoring in cardiovascular disease patients reported mean absolute errors for pulse rate near 1.06 bpm, which is well within useful range.

Blood pressure is harder. A 2024 systematic review in MDPI on non-contact vision-based vital sign monitoring found that remote blood pressure estimates typically carry mean absolute errors in the range of 5 to 12 mmHg systolic, sufficient for screening and trend detection but not for clinical diagnosis without calibration. JMIR Cardio published a cross-sectional validation of a contactless, calibration-free blood pressure and pulse rate monitor positioned for hypertension screening, reinforcing the screening-grade framing.

On the actuarial side, LexisNexis Risk Solutions reported in 2024 that combining medical and non-medical data materially improves applicant evaluation and mortality risk assessment, and Munich Re's analysis of novel attributes such as waist-to-height ratio shows the industry actively expanding beyond traditional build metrics. The throughline across this research is consistent. Biometric underwriting data delivers screening-grade physiological signal at low cost, and its protective value comes from layering and triage rather than from matching laboratory precision on any single marker.

The future of biometric underwriting data

Three developments will shape the next phase. First, protective value studies built specifically on biometric inputs will move the conversation from vendor accuracy claims to mortality-anchored evidence, which is the language reinsurers actually price on. Second, multimodal capture that fuses vitals with behavioral and wearable data will improve segmentation in the borderline band where single signals are weakest. Third, regulators and reinsurers will converge on capture-quality standards, so that signal integrity becomes auditable rather than asserted.

The likely end state is not biometric data replacing fluids wholesale. It is a tiered architecture where biometric underwriting data clears the majority of applicants cheaply and instantly, fluids are reserved for the cases where direct markers earn their cost, and protective value is measured continuously rather than assumed at launch. Carriers that instrument this measurement now will hold the credibility advantage when treaties are renegotiated.

Frequently asked questions

What is protective value in the context of biometric underwriting data?

Protective value is the mortality savings a data source produces after subtracting its cost. For biometric underwriting data, it reflects the additional impaired or borderline cases the physiological signal catches that a self-reported application would miss, weighed against the low marginal cost of capture.

Can biometric signals replace blood and urine in underwriting?

Not entirely. Biometric vitals capture screening-grade physiological signals at low cost and catch different cases than fluids, but laboratory markers such as A1C and cotinine remain the direct standard for specific impairments. Most programs use biometric data for triage and combine it with MIB, Rx, and EHR data rather than replacing fluids outright.

How accurate are contactless vitals for underwriting use?

Research shows strong agreement with ECG for pulse rate and heart rate variability, with errors near 1 bpm in validation studies. Contactless blood pressure carries larger errors, roughly 5 to 12 mmHg systolic, which supports screening and trend detection rather than clinical diagnosis. The protective value comes from triage and layering, not single-marker precision.

What should reinsurers audit in a biometric underwriting program?

Reinsurers should examine capture quality, signal stability across populations, and a documented protective value study showing which cases the biometric layer uniquely identifies. Programs that can demonstrate mortality-anchored evidence rather than vendor accuracy claims tend to secure better treaty terms.

Circadify is building protective value research specifically around contactless biometric capture for accelerated and fluidless underwriting, with the actuarial documentation reinsurers and pricing teams need to evaluate it. Reinsurers and actuaries can review the whitepapers and supporting data at circadify.com/industries/payers-insurance.